IMED licenses technology from Medarex

LinkMed’s portfolio company IMED AB has entered into an agreement with Medarex, Inc. to enable IMED AB to develop and commercialize fully human monoclonal antibodies that have been generated by IMED using Medarex’s UltiMAb® technology.

This agreement expands rights previously granted by Medarex to IMED. IMED plans to develop antibodies to a specific target identified by IMED for the treatment of immune disorders and diseases related to deregulation of cell death, e.g. transplantation and HIV.

“We are pleased to enter this agreement with Medarex, a major player within the field of antibody development,” said Lotta Ljungqvist, CEO of IMED AB. “Medarex’s UltiMAb technology has generated numerous fully human antibodies that are currently in human clinical trials. We believe that using fully human antibodies provides an advantage to us and could lead to the successful development of antibody therapeutics.”

Under the terms of the agreement, IMED will be responsible for the development and commercialization of the fully human antibody therapeutics. Medarex is entitled to receive certain license fees and milestone payments as well as royalties on commercial sales of products that may be developed under the agreement.

IMED is focused on advancing its lead project in GVHD to block apoptosis using a human monoclonal antibody generated by the use of Medarex’s UltiMAb technology. IMED is investing in its lead project, currently in a preclinical phase, and readying it for advancement to the clinical phase. GVHD is a life threatening complication after bone marrow or stem cell transplantation in which the new transplant, i.e., the graft, attacks the patient, the host, resulting in a systemic disease which affects primarily the skin, liver and gastrointestinal tract.

LinkMed owns 42.3 percent of IMED AB.


For additional information please contact:
Ingemar Lagerlöf, CEO LinkMed +46 (08) 508 939 93